Core Viewpoint - The article discusses the ambitious plans of Chasing Technology to pursue multiple IPOs for its various business units, highlighting the potential benefits and risks associated with this strategy [2][3]. Business Expansion - Chasing Technology is rapidly expanding into diverse sectors, including smartphones, astronomy, and electric vehicles, with plans to launch its first smartphone and a luxury electric vehicle by 2027 [3]. - The company aims to leverage the valuation differences across various sectors by splitting its businesses for independent IPOs, which could maximize overall company value [2]. Market Evaluation - Experts caution that while Chasing Technology has experience in hardware development, the new sectors it is entering require significant capital and technical expertise, raising questions about the feasibility of its expansion strategy [4]. - The company’s primary revenue still relies heavily on its cleaning devices, with other ventures in early investment stages, indicating a need for careful evaluation of resource allocation [3]. Risks of Expansion - There are concerns that if the core business does not establish a stable profit model, the company's aggressive expansion into high-investment areas could lead to financial risks and resource dilution [4]. - The long-term nature of some of its new ventures, such as asteroid mining, poses challenges for immediate commercialization, necessitating caution against overextending investor expectations [4]. Employee Investment Controversy - Allegations have surfaced regarding Chasing Technology's requirement for employees to invest in private equity funds, potentially linking this to job security, which raises ethical and legal concerns [6][8]. - The company has publicly denied any mandatory investment policies, asserting that participation in investment schemes is voluntary and aimed at fostering a long-term incentive structure [7][8].

上海复星医药（集团）股份有限公司 跟投管理办法 （2025年制定） 第一章 总则 第一条 为进一步规范和完善上海复星医药（集团）股份有限公司（以下简 称"本公司"）对被投企业/项目跟投的相关程序，充分调动员工积极性、激发员工 创新创业激情，保障重要投资的顺利推进，支持企业战略实现和可持续发展，根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国合伙 企业法》等适用法律法规、本公司股票上市地监管要求以及《上海复星医药（集团） 股份有限公司章程》（以下简称"《公司章程》"）的规定，特制订本办法。 本办法所称"被投企业/项目"包括跟投委员会认为对本集团（即本公司及 控股子公司/单位，下同）发展有重要影响的控股投资企业/项目、参股投资企 业/项目、以及跟投委员会认为重要的其他投资企业/项目。 第三条 本公司设立跟投委员会，由本公司执行董事、首席人力资源官组成， 负责审核、审批相关控股子公司/单位提交的有关被投企业/单位的跟投方案。 如跟投方案涉及跟投委员会成员，则该跟投方案应提交本公司董事会审议。 相关控股子公司/单位设立跟投执行小组，具体负责： （一）跟投方案的制定：涵盖跟投形式、跟投平台、持 ...